{"id":177512,"date":"2018-01-16T05:56:02","date_gmt":"2018-01-16T05:56:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=177512"},"modified":"2018-01-16T05:56:02","modified_gmt":"2018-01-16T05:56:02","slug":"global-familial-amyloid-neuropathies-drugs-and-companies-pipeline-review-h2-2018","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-familial-amyloid-neuropathies-drugs-and-companies-pipeline-review-h2-2018_177512.html","title":{"rendered":"Global Familial Amyloid Neuropathies Drugs and Companies Pipeline Review H2 2018"},"content":{"rendered":"
Pune, India, 16th January 2018: WiseGuyReports announced addition of new report, titled \u201cFamilial Amyloid Neuropathies – Pipeline Review, H2 2017\u201d.\t\t<\/div>\n

Summary<\/strong><\/p>\n

Familial amyloid neuropathy<\/a> <\/strong>is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues. Symptoms include numbness, tingling, pins and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness and fainting. Supportive treatment includes diuretics, calcium channel blockers, beta blockers, angiotensin receptor blockers and angiotensin converting enzyme (ACE) inhibitors.<\/p>\n

 <\/p>\n

GET SAMPLE REPORT @<\/em><\/strong>https:\/\/www.wiseguyreports.com\/sample-request\/2740067-familial-amyloid-neuropathies-pipeline-review-h2-2017<\/a>         <\/em><\/strong><\/p>\n

 <\/p>\n

Report Highlights<\/strong><\/p>\n

Pharmaceutical and Healthcare latest pipeline guide Familial Amyloid Neuropathies – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Familial Amyloid Neuropathies (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.<\/p>\n

 <\/p>\n

The Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected\/Withdrawn, Phase II, Phase I and Preclinical stages are 2, 1, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.<\/p>\n

 <\/p>\n

Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.<\/p>\n

 <\/p>\n

Scope<\/strong><\/p>\n

– The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Amyloid Neuropathies (Metabolic Disorders).<\/p>\n

– The pipeline guide reviews pipeline therapeutics for Familial Amyloid Neuropathies (Metabolic Disorders) by companies and universities\/research institutes based on information derived from company and industry-specific sources.<\/p>\n

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.<\/p>\n

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.<\/p>\n

– The pipeline guide reviews key companies involved in Familial Amyloid Neuropathies (Metabolic Disorders) therapeutics and enlists all their major and minor projects.<\/p>\n

– The pipeline guide evaluates Familial Amyloid Neuropathies (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.<\/p>\n

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.<\/p>\n

– The pipeline guide reviews latest news related to pipeline therapeutics for Familial Amyloid Neuropathies (Metabolic Disorders)<\/p>\n

 <\/p>\n

Reasons to buy<\/strong><\/p>\n

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.<\/p>\n

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.<\/p>\n

– Find and recognize significant and varied types of therapeutics under development for Familial Amyloid Neuropathies (Metabolic Disorders).<\/p>\n

– Classify potential new clients or partners in the target demographic.<\/p>\n

– Develop tactical initiatives by understanding the focus areas of leading companies.<\/p>\n

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.<\/p>\n

– Formulate corrective measures for pipeline projects by understanding Familial Amyloid Neuropathies (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.<\/p>\n

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.<\/p>\n

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.<\/p>\n

 <\/p>\n

Table of Content: Key Points<\/span><\/strong><\/p>\n

List of Tables<\/p>\n

List of Figures<\/p>\n

Introduction<\/p>\n

Familial Amyloid Neuropathies – Overview<\/p>\n

Familial Amyloid Neuropathies – Therapeutics Development<\/p>\n

Pipeline Overview<\/p>\n

Pipeline by Companies<\/p>\n

Pipeline by Universities\/Institutes<\/p>\n

Products under Development by Companies<\/p>\n

Products under Development by Universities\/Institutes<\/p>\n

Familial Amyloid Neuropathies – Therapeutics Assessment<\/p>\n

Assessment by Target<\/p>\n

Assessment by Mechanism of Action<\/p>\n

Assessment by Route of Administration<\/p>\n

Assessment by Molecule Type<\/p>\n

Familial Amyloid Neuropathies – Companies Involved in Therapeutics Development<\/p>\n

Alnylam Pharmaceuticals Inc<\/p>\n

Ionis Pharmaceuticals Inc<\/p>\n

Pfizer Inc<\/p>\n

Familial Amyloid Neuropathies – Drug Profiles<\/p>\n

AG-10 – Drug Profile<\/p>\n

Product Description<\/p>\n

Mechanism Of Action<\/p>\n

…Continued                             <\/strong><\/p>\n

 <\/strong><\/p>\n

ACCESS REPORT @ https:\/\/www.wiseguyreports.com\/reports\/2740067-familial-amyloid-neuropathies-pipeline-review-h2-2017<\/a>  <\/em><\/strong><\/p>\n

         <\/strong><\/p>\n

Get in touch:                                                          <\/strong><\/p>\n

LinkedIn: <\/strong>www.linkedin.com\/company\/4828928<\/strong><\/a><\/p>\n

Twitter: <\/strong>https:\/\/twitter.com\/WiseGuyReports<\/strong><\/a>                                                                   <\/strong><\/p>\n

Facebook: <\/strong>https:\/\/www.facebook.com\/Wiseguyreports-1009007869213183\/?fref=ts<\/strong>    <\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com
Contact Person:<\/strong> Norah Trent
Email:<\/strong> sales@wiseguyreports.com
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> www.wiseguyreports.com<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Pune, India, 16th January 2018: WiseGuyReports announced addition of new report, titled \u201cFamilial Amyloid Neuropathies – Pipeline Review, H2 2017\u201d. Summary Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-177512","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/177512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=177512"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/177512\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=177512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=177512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=177512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}